rTMS-augmented Written Exposure Therapy for PTSD
Post-traumatic stress disorder (PTSD) is prevalent and represents a high healthcare burden among Veterans. Repetitive transcranial magnetic stimulation (rTMS) is a brain-based therapy that may be effective for treating PTSD. The theorized mechanism of rTMS is enhancement of emotional flexibility via the dorsolateral pr
| Condition(s) | Post Traumatic Stress Disorder |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Post-traumatic stress disorder (PTSD) is prevalent and represents a high healthcare burden among Veterans. Repetitive transcranial magnetic stimulation (rTMS) is a brain-based therapy that may be effective for treating PTSD. The theorized mechanism of rTMS is enhancement of emotional flexibility via the dorsolateral prefrontal cortex node of the brain's cognitive control network. Given this mechanism of action, adding rTMS to an evidence-based psychotherapy (EBP) for PTSD may enhance treatment effects. Written exposure therapy (WET) is a brief EBP for PTSD found to reduce attrition compared to lengthier first line treatments. In this study, the investigators will determine if active rTMS added to WET compared with sham rTMS added to WET results in improved PTSD outcomes. The investigators |
| Who can participate | Inclusion Criteria: -All veterans are eligible to be included in the study if they meet all the following criteria: * veteran; * English-speaking and able to provide written informed consent; * diagnosed with PTSD; * between the ages of 18 and 60 years. Participants over age 60 will not be included, as aging is known to impact brain structure, and thus the potential accuracy of the rTMS target, independently of PTSD. Exclusion Criteria: * Individuals with history of seizures or other serious neurological history including acquired, developmental or degenerative neurologic illness, identified through medical chart review, will be excluded due to potential lowered threshold for seizures during rTMS stimulation. * The effects of rTMS are unknown on fetal development, therefore, women who are |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Lead sponsor | VA Office of Research and Development |
| Locations | Temple, Texas, United States |
| Start date | 2022-01-03 |
| NCT ID | NCT05149534 |
| Official listing | https://clinicaltrials.gov/study/NCT05149534 |